Effect of 3-[2-[4-(o-methoxyphenyl)-1-piperazinyl]ethyl]-2,4(1H,3H)- quinazolinedione monophydrochloride (SGB-1534), an antihypertensive agent, on 3H-prazosin and 3H-p-aminoclonidine binding to alpha 1- and alpha 2-adrenoceptors in dog brain and aorta.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000378:metabolism; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D003000:Clonidine / Q000031:analogs & derivatives / Q000378:metabolism; D004285:Dogs; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism; D011224:Prazosin / Q000378:metabolism; D011799:Quinazolines / Q000494:pharmacology*; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000378:metabolism*
D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; D011942:Receptors, Adrenergic, alpha; C016986:apraclonidine; C042712:SGB 1534; D003000:Clonidine; D011224:Prazosin